CA-BOLT
18.6.2024 15:03:34 CEST | Business Wire | Press release
Stellantis Financial Services US, the captive automotive finance company of Stellantis in North America, today announced a new partnership with bolt, the insurtech with the world’s largest technology-enabled insurance exchange, to support customers of Chrysler, Dodge, Jeep®, Ram, Fiat, and Alfa Romeo. bolt’s technology will enable Stellantis customers to purchase auto insurance through Stellantis brand websites and mobile apps with a panel of insurers’ products.
Through this unique partnership, the automotive insurance purchasing journey will be simplified and personalized, with custom coverage options available through multiple distribution channels. The offering will scale to include usage-based choices through the use of telematics, data and analytics.
“Stellantis customers today want choice, context, and simplicity when selecting their auto insurer,” said Mark Buffa, Managing Director of Insurance at Stellantis Financial Services US. “It’s important that insurance offerings keep up with customer demands. Partnering with bolt and their established insurer partners, we’re confident that customers and their vehicles will be better protected.”
“We are thrilled with this new partnership which reflects the Stellantis strategy to provide affordable insurance solutions and accident management solutions,” said Edouard de Lamarzelle, CEO of Stellantis Insurance.
Stellantis is focused on developing, engineering, manufacturing and scaling the best breakthroughs in all facets of sustainable mobility.
“Stellantis has an ambitious vision for how insurance can enhance their customers’ experience,” said Rob Bauer, Chief Strategic Growth Officer at bolt. “We’re honored to join Stellantis on this multi-year journey and help write the future of embedded insurance.”
By bridging the gap between all parties in the insurance ecosystem, bolt is developing modern methods of delivering insurance to customers at the point of need. bolt has grown its platform to include more than 100 insurance providers, including eight of the top 10 property and casualty insurers in the United States. With more than US$50 billion in quoted premiums on the platform annually, bolt offers over 6,000 insurance product variations and has licenses across all 50 states.
To learn more about Stellantis Financial Services, please visit www.stellantis-fs.com. To learn more about bolt, visit https://www.boltinsurance.com/.
About Stellantis Financial Services US
Stellantis Financial Services US (SFS) is wholly owned by Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP), one of the world’s leading automakers aiming to provide clean, safe and affordable freedom of mobility to all. SFS provides finance solutions for Stellantis' premier automotive brands in the United States including: Chrysler, Dodge, Jeep®, Ram, FIAT, and Alfa Romeo.
About bolt
bolt is the leading distribution platform for P&C insurance, uniting distributors and insurers to transform the way insurance is bought and sold.
The result is the world's largest tech-enabled exchange of insurance products, including two-thirds of America's leading insurers, helping businesses of all kinds distribute insurance, expand market reach, and meet more of the insurance and protection needs of customers.
For more information, visit boltinsurance.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618838215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom